IO Biotech Inc (IOBT) FinancialsIOBTFinancialIO Biotech Inc

Evaluating the bottom line, IO Biotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -240.48%, provide a clear picture of how effectively IOBT converts its operational activities into shareholder value.

In the context of the broader market, IOBT competes directly with industry leaders such as CLDI and PPCB. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, IOBT's gross margin of N/A stands against CLDI's N/A and PPCB's N/A. Such benchmarking helps identify whether IO Biotech Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, the company reported zero revenue growth, a net income drop of -65.11% YoY to -$8.38M, and an EPS decline of -63.89% YoY to -0.13. Gross margin remains at 0%.